We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

12 hedge funds and large institutions have $79.3M invested in Verona Pharma in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

20% more funds holding

Funds holding: 10 → 12 (+2)

1.33% more ownership

Funds ownership: 5.03% → 6.36% (+1.3%)

2% less capital invested

Capital invested by funds: $81M → $79.3M (-$1.75M)

Holders
12
Holders Change
+2
Holders Change %
+20%
% of All Funds
0.27%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
3
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$7.58M
2
PC
Polar Capital
United Kingdom
+$250K
3
Deutsche Bank
Deutsche Bank
Germany
+$7.79K
4
Morgan Stanley
Morgan Stanley
New York
+$13
5
UBS Group
UBS Group
Switzerland
+$13

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management III
California
-$1.04M
2
TRCT
Tower Research Capital (TRC)
New York
-$3K

VRNA Hedge Fund Activity: Q4 2017 in Review

12 of the 4,401 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2017, worth a combined $79.3M — down 2.2% from $81M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new VRNA positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was OrbiMed, adding an estimated $7.58M. The largest seller was Foresite Capital Management III, cutting an estimated $1.04M.

  • 12 institutional investors held Verona Pharma (VRNA) as of Q4 2017, up from 10 in Q3 2017.
  • Funds reported $79.3M of Verona Pharma stock for Q4 2017, down 2.2% quarter-over-quarter.
  • 3 funds opened new Verona Pharma positions in Q4 2017 and 1 closed out, a net change of +2 holders.
  • The largest Verona Pharma buyer in Q4 2017 was OrbiMed, an estimated $7.58M added.
  • The largest Verona Pharma seller in Q4 2017 was Foresite Capital Management III, an estimated $1.04M sold.

Based on aggregated 13F filings for Q4 2017.